Trial
NCT01822275
Phase II Trial of Low-Dose Whole Brain Radiotherapy With Concurrent Temozolomide and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma Multiforme
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Maryland, Baltimore
Collaborators
—
Condition
Histologically Proven Diagnosis of Glioblastoma or Gliosarcoma (WHO Grade IV)
Intervention
Chemotherapy with Temodar.
Why stopped
Poor accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-12-29